Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biomatrix (BXM) Looking Great -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (345)	2/1/1998 3:10:00 PM
From: pkwknk	Respond to of 569

..I have been told there is a CPT of about $100 above the $495 BIOX charges for the drug, but have not been able to confirm....have not seen penetration in orthopods offices...wondering why....as far as shorts, they do a lot of different things, including against the box to hold on to profit over longer time span...

To: John McCarthy who wrote (345)	2/1/1998 6:59:00 PM
From: John McCarthy	Read Replies (1) \| Respond to of 569

Does anybody know if the following is true ....... Subj: PAYING FOR IT By: TURNILOOSE Date: Jan 28 1998 7:07 P.M PST Reply To: Msg. 7 by dragon_2 DEAR MR. DRAGON, WHAT YOU SAY ABOUT INSURANCE COMPANIES NOT PAYING FOR SYNVISC IS AS ODOROUS AS DRAGON BREATH. I KNOW FOR A FACT THAT A U.S. HEALTH CARE PARTICIPANT WILL BE GETTING A $635 THREE INJECTION TREATMENT USING SYNVISC BY HIS ORTHOPDIC M.D. AND THE PARTICIPANT WILL ONLY PAY $15. K.K. Regards, John